Mallinckrodt buying Questcor Pharmaceuticals for about $5.2 billion
ANAHEIM, Calif. – Ireland’s Mallinckrodt is buying Questcor Pharmaceuticals Inc. in a deal valued at about $5.2 billion that will help to diversify its business.
Questcor stockholders will receive $30.00 per share in cash and 0.897 Mallinckrodt shares for each Questcor share they own, for a total consideration of approximately $86.10 per Questcor share. Questcor is based in California.
The companies put the transaction’s total value at about $5.6 billion.
After the deal closes, Mallinckrodt PLC shareholders will own about 50.5 per cent and former Questcor shareholders will own about 49.5 per cent of the combined company’s stock. Both companies’ boards unanimously approved the transaction.
The combined company will be headed by Mallinckrodt President and CEO Mark Trudeau. Mallinckrodt’s board will expand by three members to 12 directors.
Questcor’s stock rose slightly in Monday premarket trading.
News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.
Join the Conversation!
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.
